

ANSORP NOW

CONTENTS :

1. WHO meeting on strategies for global AMR surveillance
2. Current status of ANSORP studies
3. Publication of APFID in December 2012
4. Interesting papers
5. 9th ISAAR 2013 in Kuala Lumpur, Malaysia in March 2013

Dear ANSORP Investigators

Greetings from Seoul !
I hope all ANSORP investigators are doing well.

This is the **2012 December issue of ANSORP NOW**. It provides update information and current status of ANSORP activities. "ANSORP NOW" is a monthly newsletter, delivered to all ANSORP investigators by e-mail and website of APFID (www.apfid.org). Please read this ANSORP NOW carefully to update our international collaboration. If you have any ideas, opinions, or issues that can be shared with other ANSORP investigators, please send us e-mails or FAX.

I always appreciate your active participation in the ANSORP activities.

Wishing you and your family a happy holiday season and the New Year filled with joy and happiness. I am sending my best personal regards to all of you!

Jae-Hoon Song, MD, PhD
Organizer, ANSORP
Founder & Chairman, APFID



WHO consultation meeting on strategies for global antimicrobial resistance (AMR) surveillance

Dr. Jae-Hoon Song was invited as a Chairperson to a consultation meeting on strategies for global surveillance of AMR organized by WHO which was held on Dec 18-19, 2012 at WHO headquarters in Geneva, Switzerland. Drs. Doo Ryeon Chung and So Hyun Kim attended the meeting together with Dr. Song.

In order to improve global AMR surveillance and explore opportunities for collaboration, the existing global AMR surveillance networks and the capabilities, methods, and data that are needed to develop an effective surveillance system were reviewed and knowledge gaps related to AMR surveillance were discussed at the WHO meeting.

Contact Information

Jae-Hoon Song, MD, PhD
Organizer, ANSORP / Chairman, APFID
Samsung Medical Center
Tel: 82-2-3410-0320, FAX: 82-2-3410-0041
E-mail: ansorp@gmail.com or
songjh@skku.edu

Doo Ryeon Chung, MD, PhD
Coordinator, ANSORP
Samsung Medical Center
Tel: 82-2-3410-0323, FAX: 82-2-3410-0041
E-mail: iddrchung@gmail.com or
drchung@skku.edu

So Hyun Kim, DVM, PhD
Project Manager, ANSORP
Asia Pacific Foundation for Infectious Diseases
Tel: 82-2-3410-6826, FAX: 82-2-3410-6667
E-mail: shkim@ansorp.org or
shkim.ansorp@gmail.com



Current status of ANSORP studies

▪ A prospective, hospital-based, multicenter surveillance on antimicrobial resistance and serotypes of *S. pneumoniae* in hospitalized patients over 50 years with invasive pneumococcal diseases or pneumonia in Asia

- Principle investigator : Dr. Jae-Hoon Song (Korea)
- This study will be started early next year.

▪ A prospective multi-center, multi-national serosurvey study for pertussis among children in Asian countries

- Principle investigators : Dr. Cheng-Hsun Chiu and Dr. Chun-Yi Lu (Taiwan), Dr. Yae-Jean Kim (Korea)
- Study proposal is currently being finalized and this study can be initiated early next year.

▪ Surveillance and correlation of antibiotic prescription and Gram-negative bacterial resistance in Asian hospitals

- Principle investigator : Dr. Li Yang Hsu (Singapore)
- Budgeting and searching for sponsors are underway.

▪ Antimicrobial Stewardship Programme (ASP) in Asia: Capacity Survey

- Principle investigator : Dr. David Lye (Singapore)
- The study proposal is currently under preparation by PI.

▪ Joint CA-MRSA study : Emergence and spread of CA-MRSA clones in Asian community

- This CA-MRSA study was proposed by Dr. Teruyo Ito and Dr. Keiichi Hiramatsu at Juntendo University in Japan.
- Although Juntendo University is not an ANSORP center, ANSORP can collaborate with other organizations and this study proposal was approved by ANSORP Executive Committee has approved in December 2012.
- The purpose of this study is to investigate the epidemiology of CA-MRSA in Asian countries and specific aims are as follows:
 - To know updated information on CA-MRSA clones disseminating in Asian countries
 - To know PVL-positive CA-MRSA clone disseminating in Asian countries
 - To identify novel virulence factors

If you would like to participate in ANSORP studies and/or if you would like to submit study proposals, please contact ANSORP Project Manager (Dr. So Hyun Kim, shkim.ansorp@gmail.com).

Publication of APFID in December 2012

Bacteremic pneumonia caused by extensively drug-resistant *Streptococcus pneumoniae*

J Clin Microbiol. 2012 Dec;50(12):4175-7

Kang CI, Baek JY, Jeon K, Kim SH, Chung DR, Peck KR, Lee NY, Song JH

SUMMARY

The emergence of antimicrobial resistance threatens the successful treatment of pneumococcal infections. Here we report a case of bacteremic pneumonia caused by an extremely drug-resistant (XDR) strain of *Streptococcus pneumoniae*, non-susceptible to at least one agent in all classes but vancomycin and linezolid. This pneumococcal isolate was serotype 11A, as determined by the standard Quellung method (Statens Serum Institut, Copenhagen, Denmark). Multilocus sequence typing (MLST) of this isolate revealed ST8279, a double-locus variant of ST156 closely related to Pneumococcal Molecular Epidemiology Network (PMEN) global clone Spain9V-3.

The newly licensed pneumococcal conjugate vaccine may be effective at limiting the spread of strains with very high levels of resistance to penicillin. However, our case was not caused by the heptavalent polysaccharide conjugate vaccine serotype. Vaccine escape of XDR pneumococci such as the one reported here poses significant therapeutic challenges. This strain poses an important new public health threat in our region. More information on the emergence and spread of this XDR strain would be necessary in order to prevent its spread.

If you need PDF version of the papers, please contact ANSORP Project Manager (Dr. So Hyun Kim, shkim.ansorp@gmail.com).

Antimicrobial agent	MIC (µg/ml)	Resistance
Penicillin	4	I
Amoxicillin	16	R
Amoxicillin-clavulanate	16/8	R
Ceftriaxone	16	R
Cefuroxime	>32	R
Erythromycin	>64	R
Clarithromycin	>32	R
Tetracycline	16	R
Tigecycline	≤0.03	S
Levofloxacin	16	R
Moxifloxacin	4	R
Gatifloxacin	8	R
Ciprofloxacin	32	R
Clindamycin	>32	R
Trimethoprim-sulfamethoxazole	32/608	R
Meropenem	16	R
Imipenem	4	R
Doripenem	4	NS
Linezolid	0.5	S
Ceftobiprole	4	I
Vancomycin	0.25	S

Interesting papers - Meeting report

: 22nd European Congress of Clinical Microbiology and Infectious Diseases
(London, UK, 31 March-3 April 2012)

Global antimicrobial resistance: from surveillance to stewardship.

Part 1: surveillance and risk factors for resistance

Expert Rev Anti Infect Ther. 2012 Nov;10(11):1269-71

Cantón R, Bryan J.

ABSTRACT

As concerns about global antibiotic resistance shift from Gram-positive to Gram-negative bacteria, the annual congress of the European Society of Clinical Microbiology and Infectious Diseases, in London (UK) provided a valuable opportunity for the nearly 10,000 delegates to discuss the latest global trends. In this first report from the conference, the authors review data from the SMART trial, which recently marked a decade of monitoring antibiotic resistance of Gram-negative bacteria from intra-abdominal infections, and from the rapidly developing European Antimicrobial Resistance Surveillance Network. The authors also focus on the spread of nonmetallo- β -lactamase carbapenemases, and likely risk factors for resistance.

Global antimicrobial resistance: from surveillance to stewardship.

Part 2: stewardship initiatives

Expert Rev Anti Infect Ther. 2012 Dec;10(12):1375-7

Cantón R, Bryan J.

ABSTRACT

Twelve months after the WHO launched its World Health Day 2011 campaign to combat antimicrobial resistance, antibiotic stewardship initiatives were a major focus at the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, in London, UK. In the second part of their report from the Congress, the authors review the impact of some of these initiatives in achieving their goals of reducing overall antibiotic usage, ensuring timely, appropriate prescribing and avoiding sub-optimal dosing and unnecessarily prolonged treatment. The authors also report new data on antibiotic prescribing in primary care and latest research in the development of novel antibiotics for the future.

9th ISAAR 2013 in Kuala Lumpur, Malaysia in March 2013

We would like to cordially invite you to join the **9th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2013)**, which will be held at Kuala Lumpur Convention Center (KLCC) in Kuala Lumpur, Malaysia from March 13 to 15, 2013.

Please visit www.isaar.org for updates to the program and additional information to enhance your participation in this important meeting on infectious diseases and antimicrobial resistance. We hope that many ANSORP investigators can join the ISAAR 2013.

IMPORTANT DATES

- | | |
|------------------------------------|--------------|
| • Deadline for Abstract Submission | Jan 28, 2013 |
| • Deadline for Early Registration | Feb 20, 2013 |
| • Deadline for Late Registration | Mar 1, 2013 |



We always appreciate your active contribution to ANSORP activities.

If you have any questions, or issues that can be shared with other ANSORP investigators, please let us know them at any time.